CAMBRIDGE, UK – 13 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:
13-14 October 2016, ACC, Liverpool, UK
The Drug Discovery meeting will feature over 50 world-class speakers in six main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success. This conference will explore innovative technologies and approaches that can be used to overcome drug development challenges, and bring together industry leaders who will discuss future opportunities for novel therapeutic discovery.
19-21 October 2016, Park Plaza Riverbank, London, UK
The Lancet Neurology Conference aims to disseminate cutting-edge findings on preclinical neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. The event will provide a unique platform for specialists to come together across disciplines for an authoritative discussion of the methodological, regulatory, and ethical considerations of research in people at asymptomatic states of neurodegenerative disease.
24 October 2016, Convene Midtown East, New York, USA
Michael Koslowski, CMO, to attend the event
The Parkinson’s Disease Therapeutics Conference is The Michael J. Fox Foundation’s annual scientific conference focused exclusively on Parkinson’s disease drug development. The event brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
(4) SR One Leaders Retreat
25 October 2016, Miami, Florida, US
Anker Lundemose, CEO, to attend the event
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies.
7-9 November 2016, Cologne, Germany
Paul Wallace, CBO, to attend the conference
BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference attracts leading dealmakers from biotech, pharma and finance along with exciting emerging companies. BIO-Europe is regarded as a “must attend” event for the biotech industry.
16-17 November 2016, The Waldorf Hilton Hotel, London, UK
Anker Lundemose, CEO, and David Luther, CFO, to attend the event
The two-day event will include company presentations, thematic panel discussions, 1×1 investor meetings and, as a continuing unique feature, business-to-business meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
18 November 2016, The Waldorf Hilton Hotel, London, UK
Anker Lundemose, CEO, to present at the event
Biotech and Money are hosting the Biotech and Money Inv€$tival Showcase, in exclusive partnership with Jefferies LLC. The event showcases the latest investable public and private life science opportunities. Companies ranging from the latest start-ups through to growing public companies, will present to an audience of global investors and pharma. The conference enables investors to uncover and identify investable opportunities with 1-2-1 partnering throughout the day.
For further events, please visit the MISSION Therapeutics website
For more information:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 20 7862 6390
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.
Mission’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of Mission and is the Chief Scientific Officer of the Company.
Mission Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.